English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

One of the more exciting recent events in constitutional law has been the possibility of a newly coined constitutional right: a right of access to unproven medications. That intriguing possibility was quickly snuffed out, as the Abigail Alliance litigation drew to a close. But the issues that arose during that litigation remain important ones. This Article attempts to demonstrate that much of the claimed promise regarding a constitutional right of access to unproven medications is largely hype. For a variety of reasons, such a right is likely to have a relatively modest impact on the lives of most Americans. In contrast, however, the issue of access to unproven medications is already playing out in a surprising area that receives relatively little attention: participation in clinical research studies.

Beyond Abigail Alliance: The Reality Behind the Right to Get Experimental Drugs